[go: up one dir, main page]

Moawad, 2010 - Google Patents

Isolated system towards a successful radiotherapy treatment

Moawad, 2010

View PDF
Document ID
5399558692756732360
Author
Moawad E
Publication year
Publication venue
Nuclear Medicine and Molecular Imaging

External Links

Snippet

Purpose Establishment of the specifications and standards for successful radiotherapy treatments through identifying three objectives: administering the appropriate low-waste dose, developing dose-delivery skills and monitoring an earlier response to therapy …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A61N5/1031—Treatment planning systems using a specific method of dose optimization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1014—Intracavitary radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1075—Monitoring, verifying, controlling systems and methods for testing, calibrating, or quality assurance of the radiation treatment apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature

Similar Documents

Publication Publication Date Title
Sgouros et al. ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy
Huizing et al. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
Sgouros Dosimetry, radiobiology and synthetic lethality: radiopharmaceutical therapy (RPT) with alpha-particle-emitters
Chiesa et al. Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology
George et al. Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
Sgouros et al. Dosimetry for radiopharmaceutical therapy
Giammarile et al. Dosimetry in clinical radionuclide therapy: the devil is in the detail
Safavi-Naeini et al. Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons
Righi et al. Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications
Mattsson Patient dosimetry in nuclear medicine
Solanki et al. Cellular response to exponentially increasing and decreasing dose rates: implications for treatment planning in targeted radionuclide therapy
Ng et al. Patient dosimetry for selective internal radiation treatment based on PET imaging
Freudenberg et al. On the dose calculation at the cellular level and its implications for the RBE of 99mTc and 123I
Li et al. Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
Flux et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
De Nardo et al. A feasibility study of the therapeutic application of a mixture of 67/64Cu radioisotopes produced by cyclotrons with proton irradiation
King et al. An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology
Rumiantcev et al. Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac] Ac-PSMA and [177Lu] Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
Baun et al. Preclinical evaluation of [58mCo] Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer
Dahle et al. Relative biologic effects of low-dose-rate α-emitting 227Th-rituximab and β-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
Kim et al. Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical,[68Ga] PSMA-11, in subcutaneous prostate cancer xenograft model mice
Moawad Isolated system towards a successful radiotherapy treatment
De Nardo et al. Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases
Seniwal et al. In silico dosimetry of low-dose rate brachytherapy using radioactive nanoparticles
Bouchat et al. Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area